Results 201 to 210 of about 17,579 (227)
Some of the next articles are maybe not open access.
Gastroenterology, 2014
Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5' untranslated region-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3' untranslated region, and tested the
Li, Yi-Ping +5 more
openaire +3 more sources
Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5' untranslated region-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3' untranslated region, and tested the
Li, Yi-Ping +5 more
openaire +3 more sources
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A
Journal of Virology, 1995Two proteins, a 56-kDa protein (p56) and a 58-kDa protein (p58), are produced from the hepatitis C virus (HCV) nonstructural region 5A (NS5A). Recently, we found that both proteins are phosphorylated at serine residues and that p58 is a hyperphosphorylated form of p56.
Y, Tanji +3 more
openaire +2 more sources
Antiviral Therapy, 2017
Background Data on persistence of NS5A resistance-associated substitutions (RASs) may have implications for resistance testing approaches and selection of initial and retreatment strategies. Methods Long-term persistence of NS5A RASs in HCV genotype (GT) 1 infected subjects ( n=76) who did not achieve sustained virological response after receiving ...
David, Wyles +13 more
openaire +2 more sources
Background Data on persistence of NS5A resistance-associated substitutions (RASs) may have implications for resistance testing approaches and selection of initial and retreatment strategies. Methods Long-term persistence of NS5A RASs in HCV genotype (GT) 1 infected subjects ( n=76) who did not achieve sustained virological response after receiving ...
David, Wyles +13 more
openaire +2 more sources
In Silico Approaches to the Design of NS5A Inhibitors
Current Topics in Medicinal Chemistry, 2016In recent years, nonstructural protein 5A (NS5A) has rapidly emerged as a promising therapeutic target for Hepatitis C (HCV) virus therapy. It is involved in both viral RNA replication and virus assembly and NS5A plays a critical role in the regulation of HCV life cycle. NS5A replication complex inhibitors (NS5A RCIs) have demonstrated strong antiviral
Yan A, Ivanenkov +10 more
openaire +2 more sources
NS5A Resistance: Clinical Implications and Treatment Possibilities.
AIDS reviews, 2016Treatments with interferon-free direct-acting antiviral agents have high efficacy, with sustained virological response rates of more than 90%. Nevertheless, they fail to eliminate the infection in 1-7% of patients. The majority of virological failures are due to relapse following treatment discontinuation, while virological rebound during therapy is ...
José Luis, Calleja +3 more
openaire +1 more source
O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
Journal of Hepatology, 2015H. Dvory-Sobol +10 more
openaire +1 more source
NS5A inhibitors to treat hepatitis C virus infection
The Lancet Infectious Diseases, 2012Tania M, Welzel, Stefan, Zeuzem
openaire +2 more sources
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A
Nature, 2015David R Langley +2 more
exaly
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Nature, 2010David R Langley +2 more
exaly